Thursday, October 15, 2026

Billionaires Shift from Hawaii to Florida to Eliminate State Income Tax

Ultra-high-net-worth individuals are relocating from Hawaii to Florida to avoid state income tax, following a documented migration pattern that eliminates tax liability on investment income and capital gains. The trend could accelerate real estate appreciation in Florida's luxury markets and prompt policy responses in destination states.

LM Salvado
LM Salvado

March 17, 2026

Billionaires Shift from Hawaii to Florida to Eliminate State Income Tax
Image generated by AI for illustrative purposes. Not actual footage or photography from the reported events.

Billionaires are moving from Hawaii to Florida to eliminate state income tax obligations, according to substrate.com analysis. Florida levies no state income tax, while Hawaii's top rate reaches 11% on high earners.

The relocation pattern centers on ultra-high-net-worth individuals whose primary tax burden comes from investment income and capital gains rather than wages. A billionaire with $100 million in annual realized gains would save $11 million yearly by establishing Florida residency instead of maintaining Hawaii domicile.

Beyond income tax elimination, the migration creates secondary wealth effects. Florida residential real estate in ultra-luxury segments—properties above $20 million—could appreciate faster as UHNW buyers concentrate in limited coastal markets like Palm Beach and Miami Beach. Hawaii may face erosion of its tax base as top earners exit, potentially shifting revenue burdens to middle-income residents.

Tax migration requires more than purchasing property. Wealthy individuals must establish genuine domicile by spending 183+ days per year in Florida, registering vehicles, obtaining driver's licenses, and filing declarations of domicile. California and New York aggressively audit former residents who claim new domicile, examining credit card statements and phone location data to challenge tax residency changes.

Nine states currently levy no income tax: Alaska, Florida, Nevada, New Hampshire, South Dakota, Tennessee, Texas, Washington, and Wyoming. High-net-worth migration has concentrated in Florida, Texas, and Nevada due to climate, luxury real estate inventory, and financial services infrastructure.

The pattern may accelerate if federal capital gains rates rise. A 5-percentage-point federal increase would make state tax elimination proportionally more valuable, potentially driving additional migration. Some destination states could respond by implementing new wealth taxes or real estate transfer taxes on high-value properties, though political resistance remains strong in Republican-controlled legislatures.

Wealth managers report increased client inquiries about strategic relocation, particularly from California taxpayers facing combined federal and state rates exceeding 50% on short-term gains. The planning horizon typically spans 18-24 months to establish defensible domicile before triggering major liquidity events.

About this analysis

This is a Via News analysis. It synthesizes signals, events and patterns across our coverage rather than deriving from a single source document, so it carries no external source pointer. Via News is a conduit: where a claim traces to a specific document, we link it. How we source

LM Salvado
LM Salvado

LM Salvado is an AI possibilist — he takes the risks of AI seriously, and still sees the route through them. Founder of Via News Agency, an AI-native newsroom built on full source-traceability, he tracks how AI is reshaping markets, capital, and labor — the quiet shifts that happen before the headlines catch up.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Clinical Catalyst Season: Big-Pharma Data Flow, Regulatory Milestones, and a Thin AI-Drug Fringe
October 2026 conferences (EASD, IGCS, NACFC, HFSA) are producing a dense run of late-stage readouts from Novo Nordisk, Lilly, Roche, Bayer, Vertex and Galderma. Regulatory milestones are scheduled behind them: the ivonescimab BLA PDUFA date on 2026-11-14, FDA acceptance of Roche's vamikibart BLA, and Scholar Rock's EMA resubmission. The AI-and-finance angle is peripheral. It consists of the AI-designed drug Rentosertib and QAIAx, a speculative microcap whose trial claims (the QIII pilot, anticipated 2027-01-01, and a patent update) are forecasts and filings rather than data, so they warrant skepticism.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,375 source documents archived
Query this data → isubstrate.com